THE REGULATION OF TISSUE EOSINOPHILIA .3. INVITRO PRODUCTION OF EOSINOPHIL-DIRECTED CHEMOTACTIC INHIBITORY FACTOR BY LYMPHOCYTES-T OF COMPLETE FREUND ADJUVANT-TREATED GUINEA-PIGS

  • 1 January 1985
    • journal article
    • research article
    • Vol. 55  (1) , 115-124
Abstract
Guinea-pig spleen cells treated with complete Freund''s adjuvant (CFA) produce eosinophil-directed chemotactic inhibitory factors (ECIF). The inhibition is selective for the response of eosinophils to delayed eosinophil chemotactic factor a (ECF-a) which had been isolated from 24-h-old inflamed skin lesions induced by dinitrophenylated Ascaris extract in sensitized animals and had been confirmed as being a T lymphocyte-derived lymphokine. ECIF activity is absorbed by incubation with eosinophils, but not with macrophages or neutrophils. The cells spontaneously release ECIF; pretreatment with a protein synthesis inhibitor reduces ECIF production, indicating that protein synthesis is essential. The source of ECIF seems to be lymphocytes, probably T lymphocytes. ECIF activity is recovered in 2 separate fractions: one elutes near bovine serum albumin (MW 70,000) and the other near cytochrome c (MW 12,500). ECIF binds to peanut agglutinin- or Limulus polyphemus agglutinin-coupled agarose beads. ECIF activity is blocked when eosinophils are incubated with D-galactose or sialic acid. These results suggest that ECIF derived from T lymphocytes of CFA-treated animals modulate the delayed ECF-a-mediated tissue eosinophilia and that terminal galactose and/or sialic acid residues are essential for ECIF activity.